209 related articles for article (PubMed ID: 33685799)
1. Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
3. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
4. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
[TBL] [Abstract][Full Text] [Related]
5. Frequent PD-L1 expression in testicular germ cell tumors.
Fankhauser CD; Curioni-Fontecedro A; Allmann V; Beyer J; Tischler V; Sulser T; Moch H; Bode PK
Br J Cancer; 2015 Jul; 113(3):411-3. PubMed ID: 26171934
[TBL] [Abstract][Full Text] [Related]
6. Relationship between primary and metastatic testicular germ cell tumors: a clinicopathologic analysis of 100 cases.
Tarrant WP; Czerniak BA; Guo CC
Hum Pathol; 2013 Oct; 44(10):2220-6. PubMed ID: 23856516
[TBL] [Abstract][Full Text] [Related]
7. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II alpha expression in testicular germ cell tumors.
Dimov ND; Zynger DL; Luan C; Kozlowski JM; Yang XJ
Urology; 2007 May; 69(5):955-61. PubMed ID: 17482942
[TBL] [Abstract][Full Text] [Related]
9. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
[TBL] [Abstract][Full Text] [Related]
10. Pathologic findings and clinical outcomes in patients who required neoadjuvant chemotherapy before orchiectomy for testicular germ cell tumors.
Stump JA; Acosta AM; Whaley RD; Cheng L; Fang AM; Rais-Bahrami S; Gordetsky JB
Hum Pathol; 2022 Oct; 128():48-55. PubMed ID: 35817140
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of MDR1-expression in testicular germ cell cancer.
Schrader AJ; Seger M; Konrad L; Olbert P; Hegele A; Hofmann R; Heidenreich A
Exp Oncol; 2007 Sep; 29(3):212-6. PubMed ID: 18004247
[TBL] [Abstract][Full Text] [Related]
12. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
Shah S; Ward JE; Bao R; Hall CR; Brockstein BE; Luke JJ
Cancer Immunol Res; 2016 Nov; 4(11):903-909. PubMed ID: 27638840
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.
Balzer BL; Ulbright TM
Am J Surg Pathol; 2006 Jul; 30(7):858-65. PubMed ID: 16819328
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
[TBL] [Abstract][Full Text] [Related]
15. SALL4 is a novel diagnostic marker for testicular germ cell tumors.
Cao D; Li J; Guo CC; Allan RW; Humphrey PA
Am J Surg Pathol; 2009 Jul; 33(7):1065-77. PubMed ID: 19390421
[TBL] [Abstract][Full Text] [Related]
16. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
17. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
[TBL] [Abstract][Full Text] [Related]
18. βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; Mego M; Mardiak J
BMC Cancer; 2018 Nov; 18(1):1062. PubMed ID: 30390643
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?
Cotner CE; Hilton S; Mamtani R; Guzzo T; Vaughn DJ
Urol Oncol; 2021 Feb; 39(2):136.e11-136.e17. PubMed ID: 33308971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
